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Dear Editor:
We read with great interest the study of plecanatide, a
guanylate cyclase C (GC-C) agonist, reported by Shailub-
hai et al. [1] in the recent issue of Digestive Diseases and
Sciences. We have noticed some factually inaccurate
statements with respect to the GC-C agonist linaclotide and
the comparisons among GC-C agonists. On behalf of the
companies that market linaclotide, we felt compelled to
write to address these inaccuracies.
In the discussion section, the authors address varying
degrees of pH-dependent activity among GC-C agonists.
The GC-C binding affinities of guanylin and uroguanylin,
and the GC-C activated production of cGMP by these
endogenous hormones, have been shown to be affected by
pH [2–4]. The authors correctly note that the activity of
linaclotide is not pH dependent and that the binding
affinities of linaclotide to GC-C were similar across a
broad, physiologically relevant pH range (pH 5–8). This
pH-independence results in linaclotide being active at GC-
C along the entire longitudinal axis of the intestinal tract
[2]. However, the authors’ assertion that this pH-indepen-
dence leads to ‘‘uncontrolled activation’’ of GC-C is not
substantiated by the reference cited [2]. In fact, the pre-
clinical study cited demonstrates that linaclotide binds to
and activates GC-C in a concentration-dependent manner
[2]; in other words, the activity of linaclotide is controlled
by virtue of being delivered as a discrete oral dose.
In addition, Shailubhai et al. also put forth a theory that
the pH-independence of E. coli enterotoxin ST peptide
(ST) is the reason for extreme cases of diarrhea that can
result from enterotoxigenic E. coli (ETEC) infections. This
suggestion is not supported by previous or current research
into the causes and treatment of ETEC [5–7]. In an ETEC
infection, E. coli infects the entire intestinal tract and is
continuously replicating and secreting multiple toxins. It is
important to remember that persistent exposure to these
toxins throughout the course of an ETEC infection is not in
any way analogous to the more transient exposure to a
therapeutic GC-C agonist following a discrete oral dose [6–
8]. Furthermore, the position of Shailubhai et al. does not
take into account the proteolytic degradation that any orally
delivered GC-C agonist will undergo [8].
This is an exciting time for the field of GC-C pharma-
cology. We look forward to contributing to and reading
about future research on GC-C agonists and GC-C
pharmacology.
Reply
The communication ‘‘Clarification of Linaclotide Phar-
macology Presented in a Recent Clinical Study of Ple-
canatide’’ by Busby and Ortiz was published in response to
our article recently published in Digestive Diseases and
Sciences [1]. Busby and Ortiz called into question what
they believe to be factually inaccurate statements that they
feel ‘‘compelled’’ to address. On behalf of my colleagues, I
am equally compelled to respond to apparent misinterpre-
tations of our statements regarding the comparative char-
acteristics of guanylate cyclase-C (GC-C) agonists.
R. W. Busby (&)




Forest Research Institute, Inc., Harborside Financial Center,
Plaza V, Jersey City, NJ 07311, USA
123
Dig Dis Sci (2014) 59:1066–1067
DOI 10.1007/s10620-013-2953-x
Busby and Ortiz agree with our statement in the Dis-
cussion that, ‘‘linaclotide, a homolog of E. coli heat-stable
(ST) enterotoxin, activates GC-C receptors in a pH-inde-
pendent manner’’ but take umbrage with our including the
statement ‘‘uncontrolled manner.’’ The high incidence of
diarrhea observed in clinical evaluations with linaclotide
[9] may possibly be due to uncontrolled activation of GC-C
receptors in the GI tract due to the lack of luminal pH-
dependence of linaclotide in activation of GC-C receptors,
compared with the pH-dependence of GC-C activation by
its physiological activator uroguanylin [10]. We hypothe-
size that this loss of pH-dependence may remove a phys-
iological check on GC-C activation, which, in some cases
may be associated with severe diarrhea.
Busby and Ortiz further state that: ‘‘In fact, the pre-
clinical study cited [2] demonstrates that linaclotide binds
to and activates GC-C in a concentration-dependent man-
ner; in other words, the activity of linaclotide is controlled
by virtue of being delivered as a discrete oral dose’’.
Although Busby et al. [2] cite in vitro data to support this
supposition, there does not appear to be a significant or
consistent relationship between oral dose and physiological
response in humans. For example, using occurrence of
diarrhea as a surrogate for GC-C activation, doubling the
daily oral dose from 145 to 290 lg, had no discernible
impact on the rate of diarrhea (16 vs. 14.2 %) observed in
clinical trials [9]. Similarly, there was no apparent dose-
efficacy relationship observed for the primary endpoint
(weekly frequency of three or more complete spontaneous
bowel movements (CSBMs) and an increase of one or
more CSBMs from baseline for at least 9 weeks of the
12-week treatment period). The dose-responsiveness of
linaclotide therapy in humans is thus not well-supported by
current clinical data.
We would also like to disagree with the statement made
by Busby and Ortiz: ‘‘…Shailubhai et al. also put forth a
theory that the pH-independence of E. coli heat stable (ST)
enterotoxin is the reason for extreme cases of diarrhea that
can result from enterotoxigenic E. coli (ETEC) infections.’’
We simply speculated that the cases of severe diarrhea
observed in response to linaclotide therapy in clinical trials
may be due to the pH-independence of GC-C activation,
thus sharing the pathologic activation mechanism with ST
enterotoxin without drawing direct parallels to the mech-
anism of ETEC-associated diarrhea.
This is an exciting time for clinicians, who now or will
have available several novel compounds at their disposal
for the treatment of constipation. We hope that further
basic and clinical study will further increase the under-
standing of the mechanism of GC-C activators and con-
tinue to improve their therapeutic utility and safety.
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